Clinical trials: Solid Organ Malignancies
Insomnia, Malignant Solid Neoplasm
THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia
This phase II trial compares THC versus (vs.) THC with CBD vs. placebo to improve sleep quality for patients with solid organ cancer and insomnia.
- Trial name
- NCT07565974
- Testing
- Biospecimen Collection, Single Agent Therapy
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Mayo Clinic
Cancer, Organ Transplantation
Study of Cancers After Solid Organs Transplants
About 1500 solid organs transplants are performed each year in the Paris agglomeration. Cancer risk in the transplanted is about three times higher than in a population of the same age without any organ transplant.
- Trial name
- K-GREF (NCT00948883)
- Where
- France
- Volunteers
- 330 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunocompromised Host, Organ Transplantation
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Background: Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression End-stage renal disease…
- Conditions
- Immunocompromised Host, Organ Transplantation, Cancer
- Trial name
- NCT00904579
- Where
- 9 sites in United States
- Volunteers
- 19,929,901 people
- Sponsor
- National Cancer Institute (NCI)
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Folic acid may protect normal cells from the side effects of chemotherapy and may increase the effectiveness…
- Trial name
- NCT00024310
- Testing
- folic acid, lometrexol, paclitaxel
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Hepatic Complications, Lymphoma
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
This phase I trial is studying the side effects and best dose of temsirolimus in treating patients with metastatic solid tumor or lymphoma that cannot be removed by surgery who have different levels of liver function.
- Conditions
- Hepatic Complications, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00275093
- Testing
- temsirolimus, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs
Selumetinib and Olaparib in Solid Tumors
This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose combination of selumetinib and olaparib that can be given…
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs
- Trial name
- NCT03162627
- Testing
- Selumetinib, Olaparib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Donors, Organ Donor
Rapid Processing and Immunohistochemistry Method for Optimising Diagnosis Time in Solid Organ Donors, Suspected Malignancy
Comparison of the diagnostic yield of intra-operative histological analysis of donor tissue with suspected neoplasia performed with the standard method versus the experimental method, which involves optimisation of sample…
- Conditions
- Donors, Organ Donor, Organ Transplants
- Trial name
- NCT06734091
- Testing
- PrestoCHILL
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tumors
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of…
- Trial name
- NCT00113113
- Testing
- Rubitecan
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Solid Tumors, Metastatic Cancer to Liver
Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients
This study examines how tumors in different metastatic organs respond to immune checkpoint inhibitor (ICB) therapy in real-world clinical practice.
- Conditions
- Solid Tumors, Metastatic Cancer to Liver, Metastatic Cancer to the Bone, Metastatic Cancer to the Lung
- Trial name
- NCT07631611
- Where
- China
- Volunteers
- 938 people
- Sponsor
- Wenlong Zhong, MD
Post-transplant Lymphoproliferative Disease, Solid Organ Transplant
Bortezomib Plus Rituximab for EBV+ PTLD
Post transplant lymphoproliferative disease (PTLD) is a type of B-cell non-Hodgkin lymphoma that occurs in patients with weakened immune systems due to immunosuppressive medications taken after organ or stem cell transplantation.
- Conditions
- Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections
- Trial name
- NCT01058239
- Testing
- bortezomib, rituximab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Advanced Cancers (Solid Tumors)
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
The main purpose of this study is to determine whether, GL-ONC1, an Oncolytic Virus, can safely be administered intravenously in patients with advanced solid tumors.
- Trial name
- NCT00794131
- Testing
- GL-ONC1
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Genelux GmbH
Malignant Mast Cell Tumors, Solid Organ Sites
Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter
Background Patient satisfaction with or acceptance of care assessment is increasingly taken into account in oncology. Most cancer and other critically-ill patients require a totally-implanted Central Venous Catheter (CVC) for…
- Trial name
- QASICC-EVA (NCT01616537)
- Testing
- QUALITY OF LIFE QUESTIONNAIRE
- Where
- 10 sites in France
- Volunteers
- 990 people
- Sponsor
- Centre Antoine Lacassagne
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the bad side effects of…
- Trial name
- NCT00003144
- Testing
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- NYU Langone Health
Shingles
ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
This study evaluates if the shingles vaccine works in those persons that receive it before they receive chemotherapy for solid organ tumors.
- Trial name
- NCT02444936
- Testing
- ZOSTAVAX
- Volunteers
- 22 people
- Sponsor
- Louis Stokes VA Medical Center
High Frequency Jet Ventilation, Atelectasis
Atelectasis Formation Using HFJV During Stereotactic Solid Organ Ablations
Atelectasis formation using HFJV during stereotactic solid organ ablations. Primary endpoint will be to study the formation of atelectasis during HFJV. Secondary endpoint will be to study liver displacement over time.
- Trial name
- NCT03378752
- Testing
- HFJV
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Karolinska Institutet
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis
This trial studies how well dual energy computed tomography (DECT) works in imaging patients with solid organ cancer that has spread to the brain.
- Trial name
- NCT03685539
- Testing
- Dual-Energy Computed Tomography
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
Phase I trial to study the effectiveness of bortezomib in treating patients who have advanced cancer and kidney dysfunction. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00054483
- Testing
- bortezomib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Surgery
A Platform Study for solId orgaN CancERs
Generating bespoke biosampling protocols for individual tumour specific translational projects is onerous, cumbersome and inefficient.
- Trial name
- PINCER (NCT05650125)
- Testing
- Biosampling
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and…
- Conditions
- Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm
- Trial name
- NCT06741072
- Testing
- Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center